Similarly, while AMPK/SIRT1 activation represents an attractive metabolic target, current pharmacological activators have important restrictions: metformin is limited by the risk of lactic acidosis in advanced CKD, and agents such as AICAR have not been approved for clinical use. The gene discussed is SIRT1; the disease is chronic kidney disease.